Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 May 1;175(5):475-482.
doi: 10.1001/jamapediatrics.2020.6735.

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial

Jeffrey M Pernica  1   2 , Stuart Harman  2   3 , April J Kam  2   4 , Redjana Carciumaru  5 , Thuva Vanniyasingam  6 , Tyrus Crawford  7 , Dale Dalgleish  7 , Sarah Khan  1 , Robert S Slinger  8 , Martha Fulford  9 , Cheryl Main  10 , Marek Smieja  10 , Lehana Thabane  11 , Mark Loeb  10
Affiliations
Randomized Controlled Trial

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial

Jeffrey M Pernica et al. JAMA Pediatr. .

Abstract

Importance: Community-acquired pneumonia (CAP) is a common occurrence in childhood; consequently, evidence-based recommendations for its treatment are required.

Objective: To determine whether 5 days of high-dose amoxicillin for CAP was associated with noninferior rates of clinical cure compared with 10 days of high-dose amoxicillin.

Design, setting, and participants: The SAFER (Short-Course Antimicrobial Therapy for Pediatric Respiratory Infections) study was a 2-center, parallel-group, noninferiority randomized clinical trial consisting of a single-center pilot study from December 1, 2012, to March 31, 2014, and the follow-up main study from August 1, 2016, to December 31, 2019 at the emergency departments of McMaster Children's Hospital and the Children's Hospital of Eastern Ontario. Research staff, participants, and outcome assessors were blinded to treatment allocation. Eligible children were aged 6 months to 10 years and had fever within 48 hours, respiratory symptoms, chest radiography findings consistent with pneumonia as per the emergency department physician, and a primary diagnosis of pneumonia. Children were excluded if they required hospitalization, had comorbidities that would predispose them to severe disease and/or pneumonia of unusual origin, or had previous β-lactam antibiotic therapy. Data were analyzed from March 1 to July 8, 2020.

Interventions: Five days of high-dose amoxicillin therapy followed by 5 days of placebo (intervention group) vs 5 days of high-dose amoxicillin followed by a different formulation of 5 days of high-dose amoxicillin (control group).

Main outcomes and measures: Clinical cure at 14 to 21 days.

Results: Among the 281 participants, the median age was 2.6 (interquartile range, 1.6-4.9) years (160 boys [57.7%] of 279 with sex listed). Clinical cure was observed in 101 of 114 children (88.6%) in the intervention group and in 99 of 109 (90.8%) in the control group in per-protocol analysis (risk difference, -0.016; 97.5% confidence limit, -0.087). Clinical cure at 14 to 21 days was observed in 108 of 126 (85.7%) in the intervention group and in 106 of 126 (84.1%) in the control group in the intention-to-treat analysis (risk difference, 0.023; 97.5% confidence limit, -0.061).

Conclusions and relevance: Short-course antibiotic therapy appeared to be comparable to standard care for the treatment of previously healthy children with CAP not requiring hospitalization. Clinical practice guidelines should consider recommending 5 days of amoxicillin for pediatric pneumonia management in accordance with antimicrobial stewardship principles.

Trial registration: ClinicalTrials.gov Identifier: NCT02380352.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pernica reported receiving grant funding from bioMerieux SA for a study of enteropathogen diagnostics for children with severe gastroenteritis in Botswana outside the submitted work. Dr Loeb reported receiving personal fees from Avibr and Sunovion Pharmaceuticals Inc outside the submitted work and a contract with the World Health Organization to work on the antibiotic section of the Essential List of Medicines. No other disclosures were reported.

Figures

Figure.
Figure.. Study Flow Diagram
EDs indicates emergency departments.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429-437. doi:10.1056/NEJMra011994 - DOI - PubMed
    1. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408-416. doi:10.2471/BLT.07.048769 - DOI - PMC - PubMed
    1. World Health Organization. Pneumonia fact sheet No . 331. Published August 2, 2019. Accessed January 28, 2021. https://www.who.int/mediacentre/factsheets/fs331/en/index.html
    1. Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: the leading killer of children. Lancet. 2006;368(9541):1048-1050. doi:10.1016/S0140-6736(06)69334-3 - DOI - PubMed
    1. Bradley JS, Byington CL, Shah SS, et al. . The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the PIDS and IDSA. Clin Infect Dis. 2011;53(7):e25-e76. doi:10.1093/cid/cir531 - DOI - PMC - PubMed

Publication types

Associated data